Axonics (MEX:AXNX) Change In Payables And Accrued Expense : MXN148 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Axonics Change In Payables And Accrued Expense?

Axonics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was MXN26 Mil. It means Axonics's Accounts Payable & Accrued Expense increased by MXN26 Mil from Dec. 2023 to Mar. 2024 .

Axonics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was MXN219 Mil. It means Axonics's Accounts Payable & Accrued Expense increased by MXN219 Mil from Dec. 2022 to Dec. 2023 .

Axonics Change In Payables And Accrued Expense Historical Data

The historical data trend for Axonics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Change In Payables And Accrued Expense Chart

Axonics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

67.92

178.45

-99.25

48.74

218.99

Axonics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															102.94	-63.62	51.46	134.89	25.61

Axonics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN148 Mil.

Axonics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Axonics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Axonics (MEX:AXNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (MEX:AXNX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AXNX:USA

Address

26 Technology Drive, Irvine, CA, USA, 92618

Website

https://www.axonics.com

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.